Trimoryn reviews the dose research behind its own label: once-daily capsule, 11 ingredient amounts disclosed, no proprietary blend. U.S. availability.
AURORA, Colorado, August 10, 2026 — Trimoryn is an eleven-ingredient once-daily capsule supplying 2 billion colony-forming units from two probiotic strains alongside nine botanical, vitamin and metabolic ingredients. It is available in 60-day, 90-day and 180-day supply configurations through BuyGoods.
The prevalence of obesity among U.S. adults aged 40 to 59 was 46.4 percent during August 2021 to August 2023, higher than among adults aged 20 to 39 (35.5 percent) or 60 and older (38.9 percent), according to national survey estimates published by the National Center for Health Statistics (Emmerich, S.D., et al., 2024, “Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023,” NCHS Data Brief No. 508; cdc.gov). The same report found the prevalence of severe obesity in women (12.1 percent) to be roughly double that in men (6.7 percent).
That age and gender distribution has shifted commercial attention toward products positioned for women in midlife rather than the general adult population. Into that category, Trimoryn has announced U.S. commercial availability of its once-daily capsule, distributed through BuyGoods and taken 15 to 30 minutes before a meal. The distinguishing characteristic of the label is disclosure: every active ingredient carries its own amount, and the formula contains no proprietary blend.
→ Product information, the full supplement facts panel and current package options are published at globenewstoday.com/recommends/trimoryn/ (affiliate link; see disclosure below).
Product Overview
This release reports the commercial availability of Trimoryn in the U.S. weight management supplement market. Trimoryn is a capsule dietary supplement combining two ingredient layers: a probiotic layer of two bacterial strains totaling 2 billion CFU per serving, and a supporting layer of nine vitamin, botanical and metabolic ingredients, each itemised below.
The disclosure format is a point of difference with a regulatory dimension. Under 21 CFR 101.36, U.S. manufacturers may group ingredients into a proprietary blend and declare only its combined weight, without disclosing how much of any component it contains. The practice is legal and widespread, and it is why many supplement panels cannot be evaluated against research. Trimoryn does not use that provision: the panel gives a separate figure for each of the eleven actives, so a buyer can compare the amounts here against those used in published trials. This release performs that comparison below.
The panel lists riboflavin (vitamin B2) at 25 mg, or 1,470 percent of the daily value. Eight further non-bacterial ingredients follow: mangosteen powder at 100 mg, prickly pear extract powder 4:1 at 100 mg, cinnamon bark extract 10:1 at 100 mg, konjac extract fiber standardised to 90 percent glucomannan at 50 mg, alpha lipoic acid at 25 mg, turmeric extract standardised to 95 percent curcumin at 15 mg, berberine HCl at 15 mg, and resveratrol extract standardised to 20 percent from Polygonum cuspidatum at 12 mg. Two probiotic strains complete the formula: Bifidobacterium breve at 1 billion CFU and Akkermansia muciniphila at 1 billion CFU, for a combined 2 billion CFU per capsule. A daily value is established only for riboflavin; the remaining ten carry the panel notation indicating that no daily value has been set.
The bottle contains 30 capsules, a one-month supply at the labeled serving. The capsule shell is hypromellose, a plant-derived material rather than gelatin; remaining non-active ingredients are rice flour, silicon dioxide and magnesium stearate. The front panel carries three structure-function statements — support for fat metabolism, support for weight management, and promotion of energy and well-being — each marked with the FDA disclaimer footnote reproduced at the end of this release. It also describes the formula as containing “clinically inspired ingredients,” a phrase that describes how ingredients were selected. It is not a statement that the finished product has been clinically tested, and the manufacturer makes no such claim.
Statement from the Company
“Trimoryn was formulated around a decision we made early: disclose every amount. Proprietary blends are legal and common, and they also make it impossible for a buyer to evaluate what they are taking. We would rather publish the numbers and let people compare them. We want to be equally precise about what that does and does not mean. It means every ingredient has a research trail and a stated amount. It does not mean the finished product has been shown to reproduce the results of the studies behind those ingredients, and we make no such claim. Anyone taking prescription medication should speak with their clinician before adding this or any supplement.”
— Jason Gilbert, Product Manager, Trimoryn
Ingredient Research: Four of the Eleven Actives
This section examines four of the eleven active ingredients in research detail. It is not a review of the full formula. The four are riboflavin, the only active supplied above its established dietary requirement; cinnamon bark extract, the botanical whose disclosed amount comes closest to the range used in published trials; berberine HCl, the most extensively studied ingredient in the formula; and Akkermansia muciniphila, the ingredient behind the CFU figure in this announcement. Amounts for all eleven actives, including the seven not discussed here, appear on the supplement facts panel set out earlier in this release.
Selecting four is an editorial decision about length, not a judgement about the remaining seven, whose omission here should be read as neither endorsement nor criticism. Readers can look the other seven up against the amounts published on the panel — which is the practical point of a label without a proprietary blend.
Important qualification: all citations below describe research unaffiliated with Trimoryn, in several cases at doses substantially higher than the amounts on this label, and where that is so it is stated alongside the citation. These citations establish that these four ingredients have been studied. They say nothing about the seven not discussed here, and they are not clinical evidence that Trimoryn produces equivalent outcomes. No such equivalence is claimed.
Riboflavin (vitamin B2), 25 mg. An essential water-soluble vitamin and the precursor of flavin mononucleotide and flavin adenine dinucleotide, coenzymes required by the enzymes that carry out energy-yielding metabolism. The NIH Office of Dietary Supplements sets the recommended dietary allowance for adult women at 1.1 mg daily (Riboflavin Fact Sheet for Health Professionals, NIH ODS; ods.od.nih.gov). The 25 mg here is well above that, making riboflavin the one ingredient supplied at a dose clearly exceeding established requirements. Buyers should expect a visible, harmless consequence: excess riboflavin is excreted renally and turns urine bright yellow. That is an expected effect of the vitamin, not an indication that the product is acting on body weight.
Cinnamon bark extract 10:1, 100 mg. A 10:1 extract at 100 mg corresponds to roughly 1 g of cinnamon bark. A dose-response meta-analysis in Nutrients (Deng, M., et al., 2023, “The effect of cinnamon on glycolipid metabolism: a dose-response meta-analysis of randomized controlled trials,” doi:10.3390/nu15132983) pooled randomised trials in people with type 2 diabetes and reported reductions in triglycerides and LDL cholesterol and an increase in HDL, but no significant effect on fasting blood glucose, HbA1c or total cholesterol. An umbrella review of 21 meta-analyses found effects more pronounced above 1.5 g daily; the 1 g equivalent here sits below that threshold. Cinnamon is nonetheless the ingredient whose disclosed amount comes closest to the studied range.
Berberine HCl, 15 mg. An isoquinoline alkaloid found in Berberis and related genera. A dose-response meta-analysis in Complementary Therapies in Clinical Practice (Xiong, P., et al., 2020, “The effect of berberine supplementation on obesity indices,” 39:101113; PMID 32379652) pooled ten clinical trials and reported significant reductions in BMI (−0.29 kg/m²) and waist circumference (−2.75 cm), but no significant reduction in body weight (−0.11 kg, 95% CI −0.99 to 0.76, p = 0.79). Those trials used 1,000 to 3,000 mg daily, with better results above 1,000 mg sustained for at least twelve weeks. The amount here is 15 mg — roughly 1 to 1.5 percent of that range, a difference buyers evaluating berberine should weigh carefully.
Akkermansia muciniphila, 1 billion CFU. A mucin-degrading gut bacterium whose abundance has been inversely correlated with overweight and insulin resistance in observational work. A randomised, double-blind, placebo-controlled pilot study published in Nature Medicine (Depommier, C., et al., 2019, “Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study,” 25(7):1096–1103, doi:10.1038/s41591-019-0495-2) followed 32 of 40 overweight, insulin-resistant volunteers for three months and found daily supplementation safe and well tolerated. Two features of that trial bear directly on this product. The daily dose was 10 billion bacteria, ten times the amount here. And the improvements in insulin sensitivity and circulating lipids came from the pasteurized preparation; the live preparation did not reach significance on those endpoints, and body weight did not reach significance in either group (−2.27 kg, p = 0.091). Live organisms measured in CFU are therefore not equivalent to the preparation that produced the reported effects.
What the Evidence Base Does and Does Not Show
Full disclosure benefits a buyer only if the disclosed figures are placed next to those used in research, so that comparison is made above rather than left implied. It yields a mixed picture. Riboflavin is supplied above the recommended dietary allowance and cinnamon near the low end of the studied range, while berberine sits at roughly 1 to 1.5 percent of pooled trial doses and Akkermansia muciniphila at one tenth of its trial dose, in a live rather than pasteurized form. The same pattern applies to most of the seven ingredients not examined here.
The published findings are equally mixed and are reported as the authors stated them. The berberine meta-analysis found no significant effect on body weight, while reporting reductions in BMI and waist circumference. The cinnamon analysis found no significant effect on fasting glucose or HbA1c, while reporting changes in triglycerides and cholesterol fractions. The Akkermansia trial did not reach significance on body weight. Riboflavin’s role in energy-yielding metabolism is established rather than under investigation, but that role is a nutritional requirement and is not evidence that supplementation above requirement changes body weight.
Ingredient research is a reason to examine a formula. It is not a substitute for testing the formula itself, and no published clinical trial has evaluated Trimoryn as sold.
Format and Daily Use
Trimoryn is positioned as an addition to an established nutrition and activity routine, not a replacement for one. The manufacturer’s stated support areas are fat metabolism, weight management, and energy and well-being. Dietary pattern, energy intake, physical activity and sleep remain the established determinants of body weight, and individual experience varies with all of them as well as with medication use and general health. Anyone with a diagnosed metabolic condition, or considering a substantial change in body weight, should seek evaluation from a licensed clinician or registered dietitian rather than relying on a dietary supplement.
Market Context
The figures below, from Market Research Future and Towards Healthcare, are third-party industry context for the category, not claims by Trimoryn about its own commercial performance.
The global weight management supplement market was valued at approximately $32.32 billion in 2025 and is projected to reach $50.30 billion by 2035, at a compound annual growth rate of 4.52 percent, according to Market Research Future (Weight Management Supplement Market Report, Market Research Future, 2026; marketresearchfuture.com).
A broader assessment of dietary supplements for weight loss placed the category at approximately $145.65 billion in 2025, rising to $225.54 billion by 2035 at a compound annual growth rate of 4.47 percent, according to Towards Healthcare (Dietary Supplements for Weight Loss Market Sizing, Towards Healthcare, 2026; towardshealthcare.com). That assessment reported North America holding roughly 45 percent of the global market in 2025, herbal and plant-based products accounting for approximately 40 percent of the market by product type, and fibre-based supplements as the fastest-growing product segment.
The two figures differ by a factor of four. That is a difference in category definition rather than in the underlying commerce — the firms include different product types and channels within their scope. Both are given here because quoting either alone would suggest a precision the category does not have.
Availability and Pricing
Trimoryn is sold through the manufacturer’s authorized retail portal, with order processing handled by BuyGoods. Three package configurations are listed at the time of this release:
Two bottles (60-day supply) at $79 per bottle, $158 total, with shipping calculated at checkout
Three bottles (90-day supply) at $69 per bottle, $207 total, with free U.S. shipping
Six bottles (180-day supply) at $49 per bottle, $294 total, with free U.S. shipping
No single-bottle configuration is offered. All purchases are a one-time charge with no subscription or auto-ship enrollment applied by default. Pricing and promotional terms are set by the seller and subject to change; buyers should confirm current terms at checkout rather than relying on any third-party description, including this one.
→ Current package options, pricing and guarantee terms are listed at globenewstoday.com/recommends/trimoryn/ (affiliate link; see disclosure below).
Every order is covered by a 60-day money-back guarantee administered by the seller, and buyers should retain their order confirmation and return instructions. The guarantee should not be assumed on orders placed through another channel unless the seller confirms it in writing.
Quality and Manufacturing
The label identifies Trimoryn, of Aurora, Colorado, as the distributor. It does not state a country of manufacture, name a manufacturing facility, or carry an FDA-registration or GMP-certification statement, and no certificate of analysis or third-party testing record was published on the pages reviewed for this release.
This describes the available documentation rather than criticising it. Under 21 CFR Part 111, dietary supplement manufacturers must comply with current Good Manufacturing Practice regulations covering production standards, ingredient identity testing, quality control and accurate labeling, whether or not a claim to that effect appears on a label. Buyers wanting manufacturing records should request them from the distributor. FDA registration of a facility, where it exists, is a filing requirement and not an endorsement or evaluation of any product made there.
Transactions are processed through BuyGoods, a registered e-commerce retailer whose role does not constitute an endorsement, approval or review of the product or of any claim made in its promotion.
Usage Guidance and Safety Information
Trimoryn is intended for adult use. The label directs users to take one capsule daily, preferably 15 to 30 minutes before a meal, not to exceed the recommended dose, to store the product below 30°C (86°F), and not to use it if the safety seal is damaged or missing. It states the product is not for those under 18 or for pregnant or nursing mothers, and directs anyone taking medication or managing a medical condition to consult a physician first. Berberine in particular is generally avoided in pregnancy and nursing.
Berberine and cinnamon have both been studied in the context of glucose metabolism. Anyone taking insulin, sulfonylureas, metformin or other glucose-lowering medication should treat that as a reason to consult a prescriber, not a reason to substitute. At the amounts disclosed here, a clinically meaningful interaction from berberine is less likely than at the gram-level doses used in research, but the conversation with a prescriber remains the appropriate step. No one should adjust a prescribed regimen on the basis of a supplement.
Live probiotic supplements warrant particular caution for people who are immunocompromised, have a central venous catheter, or have a condition affecting gut barrier integrity. These individuals should speak with a physician before starting any probiotic product.
Konjac glucomannan is a viscous fibre and should be taken with adequate fluid; individuals with difficulty swallowing or a history of gastrointestinal narrowing should consult a clinician first. Individual results vary. This product is not a substitute for professional medical care and is not a treatment for any medical condition.
Scope of This Announcement
This is a product availability announcement, not a clinical trial report, an efficacy claim or an independent product evaluation. No peer-reviewed trial of the finished Trimoryn formula is cited, because the research referenced here concerns individual ingredients rather than the assembled product.
Three points bear on any evaluation. The amounts on this label are in most cases below the doses used in the research cited, stated ingredient by ingredient above. Strain identity matters in probiotic science, and both strains here are identified by species without a strain designation. And the refund guarantee applies to the authorized retail portal; third-party listings may not carry the same terms.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
Affiliate Disclosure: This press release contains a link to a retail partner website through which the distributor may receive compensation if a purchase is made following a referral, disclosed in accordance with the Federal Trade Commission’s guidelines on endorsements and testimonials (16 CFR Part 255). The affiliate relationship does not influence the factual content of this release. No compensation was provided to any researcher, journal or institution cited above, and no citation should be read as an endorsement of this product by its authors or publisher. This release is informational, is based on the product label combined with published research on the individual ingredients, and does not constitute medical or nutritional advice, diagnosis or treatment. Readers managing diabetes, prediabetes or any other metabolic condition should seek evaluation from a licensed clinician.
About Trimoryn
Trimoryn is a dietary supplement brand distributing a once-daily capsule containing riboflavin, mangosteen powder, prickly pear extract, cinnamon bark extract, konjac extract fiber, alpha lipoic acid, turmeric extract, berberine HCl and resveratrol extract, together with 1 billion CFU each of Bifidobacterium breve and Akkermansia muciniphila. Every active ingredient is disclosed with an individual amount on the supplement facts panel, and the formula contains no proprietary blend. The product is distributed through BuyGoods with a 60-day money-back guarantee. Trimoryn is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease.
Media Contact
Jason Gilbert
Product Manager, Trimoryn
Email: support@gettrimoryn.com
Order Status Inquiries: +1 (323) 391-7425
Address: 19655 E 35th Dr #100, Aurora, CO 80011, United States
Website: https://gettrimoryn.com/
For more press release distribution and guest post services, visit TS Newswire.
